Combined therapy with carvedilol and amiodarone is more effective in improving cardiac symptoms, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: Comparison with carvedilol therapy alone

Journal of Nuclear Cardiology

Volumn 15, Issue 1, 2008, Pages 57-64

  Toyama, Takuji ^a   Hoshizaki, Hiroshi ^a   Yoshimura, Yuko ^a   Kasama, Shu ^b   Isobe, Naoki ^a   Adachi, Hitoshi ^a   Oshima, Shigeru ^a   Taniguchi, Koichi ^a  

^a Gunma Pref Cardiovascular Center   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

amiodarone; carvedilol; MIBG imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMIODARONE; CARVEDILOL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; EXERCISE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART VOLUME; HUMAN; MAINTENANCE DRUG DOSE; MALE; MONOTHERAPY; PRIORITY JOURNAL; SCORING SYSTEM; SYMPATHETIC TONE;

AMIODARONE; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD PRESSURE; CARBAZOLES; CARDIOMYOPATHY, DILATED; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; STROKE VOLUME; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 38649120246     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2007.08.006     Document Type: Article

References (37)

1. Thomas J.A., and Marks B.H. Plasma norepinephrine in congestive heart failure. Am J Cardiol 41 (1978) 233-243
2. Waagstein F., Hjalmarson A., Varnauskas E., and Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37 (1975) 1022-1036
3. Swedberg K., Hjalmarson A., Waagstein F., and Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1 (1979) 1374-1376
4. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIC-II). Lancet 353 (1999) 9-13
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in congestive heart failure (MERIT-HF). Lancet 353 (1999) 2001-2007
6. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 13495
7. Packer M., Coats A.J.S., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
8. Herre J.M., Sauve M.J., Malone P., Griffin J.C., Helmy I., Langberg J.J., et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 13 (1989) 442-449
9. Singh B.N. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy. Am J Cardiol 72 (1993) 114F-124F
10. Greene H.L. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle: CASCADE Investigators. Am J Cardiol 72 (1993) 70F-74F
11. Ceremuzynski L., Kleczar E., Krzeminska-Pakula M., Kuch J., Nartowicz E., Smielak-Korombel J., et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled pilot study. J Am Coll Cardiol 20 (1992) 1056-1062
12. Pfisterer M., Kiowski W., Burckhardt D., Follath F., and Burkart F. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 69 (1992) 1399-1402
13. Massie B.M., Fisher S.G., Deedwania P.C., Simgh B.N., Fletcher R.D., Singh S.N., and CHF-STAT Investigators. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 93 (1996) 2128-2134
14. Doval H.C., Nul D.R., Grancelli H.O., Perrone S.V., Bortman G.R., Curiel R., and Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 344 (1994) 493-498
15. Singh S.N., Fetcher R.D., Fisher S.G., Singh B.N., Lewis H.D., Deedwania P.C., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 333 (1995) 77-82
16. Schofer J., Spielmann R., Schbert A., Weber K., and Schluter M. Iodine-123 metaiodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12 (1988) 1252-1258
17. Merlet P., Valette H., Dubois-Randé J.L., Moyse D., Duboc D., Dove P., et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33 (1992) 471-477
18. Germano G., Kiat H., Kavanagh P.B., Moriel M., Mazzanti M., Su H.T., et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 36 (1995) 2138-2147
19. Inoko M., Fujita M., Nakae I., Tamaki S., Watanuki M., Hashimoto T., and Konishi T. Effect of angiotensin-converting enzyme inhibition on sympathetic tone in patients with mild to moderate heart failure. Jpn Circ J 65 (2001) 39539
20. Alderman J., and Grossman W. Are beta-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy ?. Circulation 71 (1985) 854-857
21. Woodley S.L., Gilbert E.M., Anderson J.L., O'Connell J.B., Deitchman D., Yanowitz F.G., et al. Beta-blockade with bucindololin heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84 (1991) 2426-2441
22. Yamada T., Fukunami M., Ohmori M., Iwakura K., Kumagai K., Kondoh N., et al. Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta blocker therapy?. J Am Coll Cardiol 21 (1993) 628-633
23. Ungerer M., Bohm M., Elce J.S., Erdmann E., and Lohse M.J. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 87 (1993) 454-463
24. Eichhorn E.J., Heesch C.M., Barnett J.H., Alvarez L.G., Fass S.M., Grayburn P.A., et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 24 (1994) 1310-1320
25. Maisel A.S. Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of sympathetic-induced alterations of immunologic function. Circulation 90 (1994) 1774-1780
26. Sanderson J.E., Chan S.K., Yip G., Yeung L.Y., Chan K.W., Raymond K., et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 34 (1999) 1522-1528
27. Kukin M.L., Kalman J., Charney R.H., Levy D.K., Buchholz-Varley C., Ocampo O.N., et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99 (1999) 2645-2651
28. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., and Cas L.D. Differential effects of beta blockers in patients with heart failure. A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102 (2000) 546-551
29. Gilbert E.M., Abraham W.T., Olsen S., Hattler B., White M., Mealy P., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94 (1996) 2817-2825
30. Freedman M., and Somberg J.C. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol 31 (1991) 1061-1069
31. Singh S.N., and Bennett B.H. Ventricular arrhythmias associated with congestive heart failure: the role for amiodarone. J Clin Pharmacol 31 (1991) 1109-1111
32. Nademanee K., Singh B.N., Callan B., Hendrickson J.A., and Hershman J.M. Amiodarone, thyroid hormones indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias. Am J Cardiol 58 (1986) 981-986
33. Ide T., Tsutsui H., Kinugawa S., Kinugawa S., Utsumi H., and Takeshita A. Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action. Circulation 100 (1999) 690-692
34. Ohyama K., Nakajima M., Suzuki M., Shimada N., Yamazaki H., and Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interaction. Br J Clin Pharmacol 49 (2000) 244-253
35. Oldham H.G., and Clarke S.E. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos 25 (1997) 970-977
36. Zhou H.H., and Wood A.J.J. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 57 (1995) 518-524
37. Fukumoto K., Kobayashi T., Komamura K., Kamakura S., Kitakaze M., and Ueno K. Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. Drug Metab Pharmacokinet 20 (2005) 423-427